An assay for the autoubiquitination activity of the E3 ligase HDM2 (Mdm2) was developed and adapted to a high-throughput format to identify inhibitors of this activity. The assay can also be used to measure the activity of other E3s and may be useful in finding both inhibitors and activators of a wide range of different ubiquitin ligases. (Journal of Biomolecular Screening 2004:695-703) 
INTRODUCTION
P OSTTRANSLATIONAL MODIFICATIONS PLAY AN IMPORTANT ROLE in regulating protein function and biological processes. Numerous modifications have been described, including modification by covalent attachment of polypeptides such as ubiquitin and SUMO. 1 Ligation of ubiquitin can target proteins for degradation by the proteasome and so plays a key role in the regulation of protein stability. 2 Many proteins that regulate cell growth and cell death have been shown to be controlled at the level of protein stability by ubiquitination, 3, 4 and perturbation of this regulation can contribute to a wide range of diseases, including cancer. 5, 6 The process of ubiquitination therefore presents some attractive targets for the development of novel therapeutics.
The ubiquitin pathway involves a relatively simple cascade of 3 enzymes: the ubiquitin activating enzyme (E1), a family of ubiquitin-conjugating enzymes (E2s), and a much larger family of ubiquitin ligases (E3s), which allow conjugation of ubiquitin to the target the protein through an isopeptide bond. 7 Recognition of tagged proteins by the proteasome requires the formation of polyubiquitin chains-monoubiquitination may also regulate protein function by targeting proteins to specific subcellular locations. 8 The target specificity of ubiquitination is determined by the E3s, which fall into 2 main groups: the HECT domain proteins and RING domain proteins. 9 The therapeutic potential for the modulation of protein stability has been illustrated by the success of clinical trials with the proteasome inhibitor, although this is an extremely nonspecific approach to preventing protein degradation. 10 Targeting the E3 proteins is likely to allow far greater selectivity for the modulation of stability of specific proteins, and we describe here an assay that could be adapted to screen for small-molecule inhibitors of E3.
The assay was developed to measure the activity of the RING domain E3 HDM2. HDM2 (Mdm2 in mice) is necessary for the degradation of tumor suppressor p53, and activation of p53 is associated with inhibition of HDM2 function. 11 In some tumors, failure to inactivate HDM2 leads to a failure to induce p53, and inhibition of HDM2 expression has been shown to activate p53 in these cells. [12] [13] [14] We would therefore predict that small-molecule inhibitors of HDM2 would allow p53 stabilization in these tumors and activation of p53 growth suppressor functions. Like many other RING domain E3s, HDM2 shows autoubiquitination activity, 15 and the RING domain that is required for p53 ubiquitination is also necessary for autoubiquitination activity. Small proteins such as ARF and L11, which bind HDM2, also block HDM2's E3 activity, [16] [17] [18] [19] [20] leading to the stabilization of both p53 and HDM2. Despite the increase in both proteins and the apparent retention of the interaction between p53 and HDM2-which would be expected to inhibit p53 function-the net result of ARF and L11 expression is activation of a p53 response. [19] [20] [21] [22] These observations suggest that inhibitors of HDM2 autoubiquitination will also stabilize p53 and allow induction of a p53-mediated growth inhibitor response. The assay was therefore developed to measure autoubiquitination of HDM2, although other E3s could successfully be substituted for HDM2.
MATERIALS AND METHODS

Materials
Rabbit E1 was purchased from Calbiochem. GST-HDM2 and UbcH5B 23 were expressed in Escherichia coli, and bacterial lysates were prepared as described. 15 The GST-XIAP, GST-NEDD4, and GST-Praja1 fusions were as previously described. [24] [25] [26] ORIGEN-tag-labeled antibody against ubiquitinated proteins was from Meso Scale Discovery (MSD), and 2.8-µm glutathionecoated paramagnetic beads were obtained from IGEN International (Gaithersburg, MD).
Fluorescent assay for HDM2 self-ubiquitination
First, 250 µL of a glutathione sepharose bead slurry was washed 3 times in 1 mL of wash buffer (50 mM Tris-HCl [pH 8.0], 2 mM Dithiothreitol, 5 mM MgCl 2 , 100 mM NaCl, 1% Triton X100). Then, 1.5 mL of a bacterial lysate containing GST-HDM2 was added to the beads and mixed at 4°C for 1 h. The beads were then washed once in a 1-mL wash buffer and spilt into 10 reactions, which were resuspended in a 25-µL reaction buffer (50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 mM DTT, 5 mM MgCl 2 , 1 mM adenosine triphosphate [ATP]) containing 50 ng E1 (Calbiochem), 1 µL UbcH5B lysate, and 1 µg His 6 ubiquitin (Affiniti). After a 30min incubation at 37°C, the reaction was stopped by dilution into 0.8 mL cold stop buffer (phosphate-buffered saline [PBS]-0.05% Tween-20). After removing all but 100 µL of the supernatant, 500 µL of India-HRP detection reagent (Pierce, diluted 1:2000 in wash buffer) was added and incubated for 15 min. After washing 3 times with 1 mL wash buffer, beads were resuspended in 100 µL wash buffer; then, 20 µL was added to a 90-µL QuantaBlu fluorescent substrate (Pierce; diluted 1 mL QuantaBlu peroxide to 10 mL in substrate), and fluorescence was measured at 30°C, with excitation 320 nm and emission 460 nm.
Electrochemiluminescence assay for HDM2 self-ubiquitination
Glutathione-coated paramagnetic beads were incubated with GST-HDM2 bacterial lysate followed by extensive washes. In a typical assay, 10-to 20-µg GST-HDM2-coated beads were mixed with 4 ng E1 and 0.1 µL UbcH5B lysate in a 10-µL reaction buffer (50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 5 mM MgCl 2 , 1 mM ATP, 2 mM DTT) in each well of a polypropylene U-bottom 96well plate. Each compound was added in 5 µL of 50% DMSO. Reactions were initiated by the addition of 5 µL 2 µM Ub in reaction buffer and allowed to proceed for 1 h at room temperature. Next, 10 to 100 ng of ORIGEN-tag-labeled antibody against ubiquitinated proteins was added in 130 µL PBS containing 0.1% bovine serum albumin (BSA), 0.2% Tween-20, and 20 mM ethylenediamine tetraacetic acid (EDTA) followed by incubation for 1 h at room temperature. Electrochemiluminescence signals were measured with an ORIGEN M-8 Analyzer (IGEN International, Gaithersburg, MD).
High-throughput screening
A library of 100,000 compounds was screened at a concentration of 40 µM on Biomek FX automation. "Hits" were selected based on at least 50% inhibition of the electrochemiluminescence signal obtained in compound-free control wells. Random portions of the library were screened in duplicate to demonstrate the reproducibility of the assay format. A counterscreen against NEDD4 was run in high throughput using a subset of compounds to determine the specificity of putative inhibitors.
RESULTS
Development of an in vitro assay for HDM2 autoubiquitination activity
The ability of HDM2 to function as a ubiquitin ligase for itself and p53 has been reported in the literature by us and others. 15, 27 These assays use a gel-based protocol in which p53 or HDM2 is ubiquitinated in an in vitro reaction and the presence of higher molecular weight, ubiquitinated forms of the protein detected on polyacrylamide gels. This is a sensitive but time-consuming and laborious assay not well suited for large-scale screening. We therefore developed an alternative assay for HDM2 autoubiquitination activity that is amenable to adaptation for large-scale highthroughput screening (HTS).
In the first version of the assay, bacterially expressed GST-HDM2, E1 (purchased from Calbiochem), bacterially expressed UbcH5B (E2), and His-tagged ubiquitin (purchased from Affiniti Research) were incubated, and after washing, the bound ubiquitin was detected using horseradish peroxidase and the fluorescent substrate QuantaBlu (Pierce; excitation 320 nm, emission 460 nm). Initial optimization of the assay conditions was carried out in 30-µL reactions (Fig. 1 ). After optimization, the assay showed a good range of activation and excellent reproducibility ( Fig. 2A ). An HDM2 protein with a mutation in the RING domain that has previously been shown to destroy E3 activity had no activity in this assay ( Fig. 2A) .
Although the E2 used by HDM2 in cells is not known, the E2 UbcH5B has been used previously and also functions in our assays. To determine whether HDM2 could function with any E2, we tested the activity of UbcH7 in our assay ( Fig. 2B ). Neither UbcH7 nor a mutant of UbcH5B supported HDM2 ubiquitination, although the UbcH7 was functional with the HECT domain E3 E6AP (data not shown). HDM2 therefore shows some selectivity for E2s in this assay.
Activity of other RING domain proteins
We were also interested to see whether the assay could be adapted to measure the autoubiquitination activity of other E3s. Substituting other known E3 ligases such as Praja1 or XIAP for HDM2 in the assay demonstrated robust ubiquitination activity for each of these E3s (Fig. 3) . Interestingly, we were also able to detect strong ubiquitination activity for the isolated HDM2 RING domain alone.
The HDM2-related protein HDMX also contains a RING finger region similar to that found in HDM2 through which the 2 proteins can interact. 28 The ability of HDMX to function as a ubiquitin ligase has been somewhat controversial. [29] [30] [31] In agreement with the results from other in vitro assays, 32 HDMX showed no E3 activity in the present assay (Fig. 4A) . The difference in activity between HDM2 and HDMX could be localized to the RING domain because the activity of chimeric HDM2/HDMX proteins in which the RING domains were exchanged correlated with the presence of the HDM2 RING (Fig. 4B )-although this chimera cannot degrade p53. A potential nucleotide binding site is present in the RING domain of HDM2, and a critical lysine at amino acid 454 is substituted for an arginine in HDMX. To determine whether this is critical in determining the lack of activity of HDMX, we exchanged this residue in HDM2 and HDMX. However, exchange of these residues had no detectable impact on the activity of either HDM2 or HDMX (Fig. 4C) . 
Assay for Ubiquitin Ligase Activity
Adaptation of assay to high-throughput format
To adapt the assay for the HTS of potential small-molecule inhibitors of HDM2, we turned to ORIGEN-based technology for the detection of ubiquitinated HDM2. Briefly, GST-HDM2 was attached to glutathione-coated paramagnetic beads, and after washing, the beads were mixed with E1, E2, and ATP-containing buffer in a 10-µL volume per assay. Where appropriate, potential smallmolecule inhibitors were added in 5 µL, and the reaction was started by adding 5-µL ubiquitin. After a 1-h incubation at room temperature, EDTA and ORI-TAG-labeled ubiquitin antibody against ubiquitinated proteins in 130 µL was added. After a 1-h incubation at room temperature the ECL-generated signals were read in an M8 analyzer. Using HDM2, the signal-to-background ratio in this assay was more than 100 ( Fig. 5A ). As shown in Figure  1 , the activity was dependent on an intact RING domain of HDM2 and was lost by the HDM2-H457S mutant. An unrelated RING domain E3, XIAP, showed even higher activity in this assay (Fig.  5A) . The reaction showed linear kinetics with or without shaking over the first 60 min (Fig. 5B) , and the assay signal was stable overnight at room temperature (Fig. 5C ). Further optimization for E1 and E2, ubiquitin, and ATP concentration were carried out prior to use of the assay as a screen (Fig. 6 ). Although both fluorescent and ECL assays had excellent signal-to-background ratios and Z′ scores (0.9 for the fluorescent assay and 0.76 for the ECL assay), we chose to use the ECL assay because it was more economical in reagent use, and the instrumentation for the ECL assay was designed for HTS and easily integrated into other automation to allow minimal user intervention.
Utility of the assay for small-molecule screens
To assess the utility of this assay for the HTS of E3 inhibitors, a pilot study was undertaken using 4700 compounds from the IGEN library. The compounds were screened in duplicate at 10-to 30-µM concentrations. The assay showed excellent reproducibility (Fig. 7A) , with an average Z′ value of 0.76 (Fig. 7B) .
The assay was designed to function with excess E1 and E2 to reduce the likelihood of identifying inhibitors of these enzymes. To assess the specificity of some of the compounds identified in this initial screen, we compared the kinetics of the inhibition of HDM2 to the inhibition of XIAP under otherwise identical conditions (Fig. 8A,B) . These assays showed that all 3 compounds, which were not structurally related, showed activity in inhibiting HDM2; compound A displayed partial inhibition, whereas compounds B and F displayed complete inhibition of the assay signal. Two of the compounds (compounds A and B) showed a much lower activity against XIAP, indicating some specificity toward HDM2. However, one of the compounds (compound F) was effective in the inhibition of both HDM2 and XIAP. This compound may be a nonspecific inhibitor, but it is also possible that compounds with this activity may function through the inhibition of other common components of the assay such as E1 or E2. Further investigation would be required to determine the mechanism of action of this compound. In initial experiments in cells, we were unable to detect a reproducible effect of these compounds on the activity of HDM2, although the uptake, stability, and availability of the compounds in cells were not examined further.
Because nonspecific inhibitors of ubiquitination were detected in this preliminary screen, we sought to adapt the original screen to more clearly identify compounds that showed selectivity for HDM2. Using a new chemical library, we therefore ran screens in parallel against both HDM2 and Nedd4 (Fig. 9) . The results showed that although the majority of compounds had no clear effect on the activity of either of these E3s, 3 classes of compounds could be identified: those that reduced HDM2 activity to less than 50% but did not affect Nedd4 activity (specific for HDM2), those that reduced Nedd4 activity to less than 50% but did not affect HDM2 (specific for Nedd4), and those that inhibited both E3s to less than 50% (nonspecific inhibitors). Interestingly, this assay also revealed a few compounds that appeared to increase the activ-ity of Nedd4 to more than 200%. Although further characterization of these groups of compounds is required, these initial results suggest that double screening in this way will eliminate some nonspecific inhibitors of the ubiquitination reaction.
DISCUSSION
Posttranslational modifications play important roles in regulating protein function and biological processes. Modulation of this activity by small molecules designed to inhibit the activity of enzymes responsible for protein modification is a key goal for the de-velopment of therapeutic agents. The best examples of these so far are small-molecule kinase inhibitors that prevent phosphorylation. 33 We describe here a simple and efficient assay that can be used to screen for inhibitors of ubiquitin ligases. The assay was validated using HDM2, an E3 for p53, although other RING domain E3s also functioned efficiently in the assay. Previous studies have identified inhibitors of HDM2's ability to ubiquitinate p53, although these compounds did not block HDM2 autoubiquitination as described in our study. 34 A pilot screen of a small-molecule library showed that the assay could be successfully adapted to a high-throughput format and used to identify small-molecule HDM2 inhibitors with a high degree of reproducibility. Because the assay involves several enzymes, it is possible that other steps in the ubiquitin cascade are being inhibited. To some extent, we have avoided this problem by limiting the amount of HDM2 in the reaction, making this the limiting component. However, a counterscreen of all the compounds against an unrelated E3 using the same E1 and E2 enzymes proved extremely efficient in distinguishing compounds that specifically inhibited only 1 E3-and are therefore likely to be specific-from those that inhibited both E3s and are therefore candidates for general E3 inhibitors or inhibitors of other steps in the pathway such as the E1 or E2. Furthermore, initial screens suggested that the assay might also be useful in identifying activators of E3s, providing the possibility of inducing E3 activity and protein degradation.
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